Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: nitric oxide synthase type II inhibitors - DSX Therapeutics

Drug Profile

Research programme: nitric oxide synthase type II inhibitors - DSX Therapeutics

Alternative Names: Anti-iNOS monoclonal antibodies; aSeptiMab®; DSX A; DSX D; DSX I; iNOS inhibitors - DSX Therapeutics

Latest Information Update: 16 Jul 2016

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator DSX Therapeutics LLC
  • Class Monoclonal antibodies
  • Mechanism of Action Nitric oxide synthase type II inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Sepsis

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Sepsis in USA (IV)
  • 27 Jun 2015 aSeptiMab® is available for licensing as of 24 Jun 2015. www.dsxtherapeutics.com
  • 27 Jun 2015 DSX Therapeutics plans a phase I trial for Sepsis in USA and Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top